Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Staskin

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Neurourology and Urodynamics|December 9, 2025
Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE TrialEric S Rovner, Janet Owens-Grillo, Elizabeth Thomas, et al.
Advances in Therapy|March 23, 2024
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims AnalysisBenjamin Chastek, Adam Carrera, Christina Landis, et al.
Neurourology and Urodynamics|May 9, 2024
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims studyBenjamin Chastek, Adam Carrera, Christina Landis, et al.
European Urology|October 23, 2019
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or PlaceboChristopher R Chapple, Francisco Cruz, Linda Cardozo, et al.
European Urology|August 17, 2019
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence AssessmentChristian Gratzke, Christopher Chapple, Elizabeth R Mueller, et al.
European Urology|March 12, 2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)Paul Abrams, Con Kelleher, David Staskin, et al.
World Journal of Urology|August 26, 2025
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomesBenoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
World Journal of Urology|November 3, 2025
Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomesBenoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
International Urogynecology Journal|May 27, 2014
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladderLinda Cardozo, David Staskin, Brooke Currie, et al.
International Journal of Clinical Practice|June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR TrialDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Neurourology and Urodynamics|December 9, 2025
Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE TrialEric S Rovner, Janet Owens-Grillo, Elizabeth Thomas, et al.
Advances in Therapy|March 23, 2024
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims AnalysisBenjamin Chastek, Adam Carrera, Christina Landis, et al.
Neurourology and Urodynamics|May 9, 2024
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims studyBenjamin Chastek, Adam Carrera, Christina Landis, et al.
European Urology|October 23, 2019
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or PlaceboChristopher R Chapple, Francisco Cruz, Linda Cardozo, et al.
European Urology|August 17, 2019
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence AssessmentChristian Gratzke, Christopher Chapple, Elizabeth R Mueller, et al.
European Urology|March 12, 2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)Paul Abrams, Con Kelleher, David Staskin, et al.
World Journal of Urology|August 26, 2025
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomesBenoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
World Journal of Urology|November 3, 2025
Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomesBenoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, et al.
International Urogynecology Journal|May 27, 2014
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladderLinda Cardozo, David Staskin, Brooke Currie, et al.
International Journal of Clinical Practice|June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR TrialDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
Pageof 6